Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs

Journal of Controlled Release

Volumn 187, Issue , 2014, Pages 145-157

  Markovsky, Ela ^a   Baabur Cohen, Hemda ^a   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer treatment; Chemotherapy; Combination therapy; Drug polymer conjugates; Polyglutamic acid; Polymeric nanomedicines

Indexed keywords

BIOCOMPATIBILITY; CHEMOTHERAPY; CONJUGATED POLYMERS; FUNCTIONAL POLYMERS; MEDICAL NANOTECHNOLOGY; MIXTURES; ONCOLOGY; PHARMACOKINETICS; TUMORS;

COMBINATION THERAPY; DRUG-POLYMER CONJUGATES; ENHANCED PERMEABILITY AND RETENTION EFFECTS; EQUIVALENT CONCENTRATIONS; NANOMEDICINES; PHYSICOCHEMICAL PROPERTY; POLYGLUTAMIC ACIDS; POLYMER THERAPEUTIC;

DRUG INTERACTIONS;

DOXORUBICIN; PACLITAXEL; POLYGLUTAMIC ACID; RNA; ANTINEOPLASTIC AGENT; DRUG COMBINATION; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER LOCALIZATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG RELEASE; DRUG RETENTION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR SIZE; MOUSE; NANOMEDICINE; NONHUMAN; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; ADENOCARCINOMA; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; HUMAN; MAMMARY NEOPLASMS, ANIMAL; NUDE MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE, NUDE; NANOMEDICINE; PACLITAXEL; POLYGLUTAMIC ACID; POLYMERS;

EID: 84902215667     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.025     Document Type: Article

References (49)

1. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
2. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 65 2000 271 284 (Pubitemid 30122932)
3. E. Markovsky, H. Baabur-Cohen, A. Eldar-Boock, L. Omer, G. Tiram, S. Ferber, P. Ofek, D. Polyak, A. Scomparin, and R. Satchi-Fainaro Administration, distribution, metabolism and elimination of polymer therapeutics J. Control. Release 161 2012 446 460
4. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Deliv. Rev. 65 2013 71 79
5. D. Polyak, A. Eldar-Boock, H. Baabur-Cohen, and R. Satchi-Fainaro Polymer conjugates for focal and targeted delivery of drugs Polym. Adv. Technol. 24 2013 777 790
6. R. Duncan, and M.J. Vicent Polymer therapeutics - prospects for 21st century: the end of the beginning Adv. Drug Deliv. Rev. 65 2013 60 70
7. J. Kopecek, P. Kopeckova, T. Minko, Z.R. Lu, and C.M. Peterson Water soluble polymers in tumor targeted delivery J. Control. Release 74 2001 147 158 (Pubitemid 32727617)
8. J. Kopecek Polymer-drug conjugates: origins, progress to date and future directions Adv. Drug Deliv. Rev. 65 2013 49 59
9. F. Greco, and M.J. Vicent Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines Adv. Drug Deliv. Rev. 61 2009 1203 1213
10. F. Kratz, and A. Warnecke Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems J. Control. Release 164 2012 221 235
11. A. Eldar-Boock, D. Polyak, A. Scomparin, and R. Satchi-Fainaro Nano-sized polymers and liposomes designed to deliver combination therapy for cancer Curr. Opin. Biotechnol. 24 2013 682 689
12. S.G. Arbuck Taxol (paclitaxel): future directions Ann. Oncol. 5 Suppl. 6 1994 S59 S62
13. R.B. Weiss The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19 1992 670 686 (Pubitemid 23004844)
14. C. Jin, H. Li, Y. He, M. He, L. Bai, Y. Cao, W. Song, and K. Dou Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo J. Cancer Res. Clin. Oncol. 136 2010 267 274
15. H. Wang, Y. Zhao, Y. Wu, Y.L. Hu, K. Nan, G. Nie, and H. Chen Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles Biomaterials 32 2011 8281 8290
16. J. Jassem, T. Pienkowski, A. Pluzanska, S. Jelic, V. Gorbunova, J. Berzins, T. Nagykalnai, L. Biganzoli, A. Aloe, L. Astier, and S. Munier Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial Onkologie 32 2009 468 472
17. J. Jassem, T. Pienkowski, A. Pluzanska, S. Jelic, V. Gorbunova, Z. Mrsic-Krmpotic, J. Berzins, T. Nagykalnai, N. Wigler, J. Renard, S. Munier, and C. Weil Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial J. Clin. Oncol. 19 2001 1707 1715 (Pubitemid 32230871)
18. L. Gianni, E.H. Herman, S.E. Lipshultz, G. Minotti, N. Sarvazyan, and D.B. Sawyer Anthracycline cardiotoxicity: from bench to bedside J. Clin. Oncol. 26 2008 3777 3784
19. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598 (Pubitemid 32778603)
20. J.M. Buescher, and A. Margaritis Microbial biosynthesis of polyglutamic acid biopolymer and applications in the biopharmaceutical, biomedical and food industries Crit. Rev. Biotechnol. 27 2007 1 19 (Pubitemid 46425931)
21. A. Eldar-Boock, K. Miller, J. Sanchis, R. Lupu, M.J. Vicent, and R. Satchi-Fainaro Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel Biomaterials 32 2011 3862 3874
22. C. Li Poly(l-glutamic acid)-anticancer drug conjugates Adv. Drug Deliv. Rev. 54 2002 695 713 (Pubitemid 35247523)
23. T. Strojnik, I. Zajc, A. Bervar, B. Zidanik, R. Golouh, J. Kos, V. Dolenc, and T. Lah Cathepsin B and its inhibitor stefin A in brain tumors Pflugers Arch. 439 2000 R122 R123
24. T. Strojnik, J. Kos, B. Zidanik, R. Golouh, and T. Lah Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors Clin. Cancer Res. 5 1999 559 567 (Pubitemid 29131965)
25. J. Decock, N. Obermajer, S. Vozelj, W. Hendrickx, R. Paridaens, and J. Kos Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer Int. J. Biol. Markers 23 2008 161 168
26. J.A. Foekens, J. Kos, H.A. Peters, M. Krasovec, M.P. Look, N. Cimerman, M.E. Meijer-van Gelder, S.C. Henzen-Logmans, W.L. van Putten, and J.G. Klijn Prognostic significance of cathepsins B and L in primary human breast cancer J. Clin. Oncol. 16 1998 1013 1021 (Pubitemid 28108735)
27. M. Markman Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103 J. Exp. Ther. Oncol. 4 2004 131 136 (Pubitemid 39079049)
28. V.L. Galic, J.D. Wright, S.N. Lewin, and T.J. Herzog Paclitaxel poliglumex for ovarian cancer Expert Opin. Investig. Drugs 20 2011 813 821
29. C.J. Langer, K.J. O'Byrne, M.A. Socinski, S.M. Mikhailov, K. Lesniewski-Kmak, M. Smakal, T.E. Ciuleanu, S.V. Orlov, M. Dediu, D. Heigener, A.J. Eisenfeld, L. Sandalic, F.B. Oldham, J.W. Singer, and H.J. Ross Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer J. Thorac. Oncol. 3 2008 623 630 (Pubitemid 351787307)
30. S. Jeyapalan, J. Boxerman, J. Donahue, M. Goldman, T. Kinsella, T. Dipetrillo, D. Evans, H. Elinzano, M. Constantinou, E. Stopa, Y. Puthawala, D. Cielo, A. Santaniello, A. Oyelese, K. Mantripragada, K. Rosati, D. Isdale, and H. Safran Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study Am. J. Clin. Oncol. 2013 10.1097/COC.0b013e31827de92b [in press]
31. M.J. Vicent, F. Greco, R.I. Nicholson, A. Paul, P.C. Griffiths, and R. Duncan Polymer therapeutics designed for a combination therapy of hormone-dependent cancer Angew. Chem. Int. Ed. Engl. 44 2005 4061 4066 (Pubitemid 40886448)
32. T. Lammers, V. Subr, K. Ulbrich, P. Peschke, P.E. Huber, W.E. Hennink, and G. Storm Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers Biomaterials 30 2009 3466 3475
33. A. Ponta, and Y. Bae PEG-poly(amino acid) block copolymer micelles for tunable drug release Pharm. Res. 27 2010 2330 2342
34. W. Song, Z. Tang, M. Li, S. Lv, H. Sun, M. Deng, H. Liu, and X. Chen Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects Acta Biomater. 10 2014 1392 1402
35. Y. Zhou, J. Yang, J.S. Rhim, and J. Kopecek HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects J. Control. Release 172 2013 946 953
36. G. Bulaj, T. Kortemme, and D.P. Goldenberg Ionization-reactivity relationships for cysteine thiols in polypeptides Biochemistry 37 1998 8965 8972 (Pubitemid 28299665)
37. D. Willner, P.A. Trail, S.J. Hofstead, H.D. King, S.J. Lasch, G.R. Braslawsky, R.S. Greenfield, T. Kaneko, and R.A. Firestone 6-Maleimidocaproyl) hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin Bioconjug. Chem. 4 1993 521 527 (Pubitemid 2018209)
38. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
39. F. Greco, M.J. Vicent, S. Gee, A.T. Jones, J. Gee, R.I. Nicholson, and R. Duncan Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells J. Control. Release 117 2007 28 39 (Pubitemid 46164864)
40. Y. Bae, T.A. Diezi, A. Zhao, and G.S. Kwon Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents J. Control. Release 122 2007 324 330 (Pubitemid 47404677)
41. F. Ahmed, R.I. Pakunlu, A. Brannan, F. Bates, T. Minko, and D.E. Discher Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug J. Control. Release 116 2006 150 158 (Pubitemid 44868999)
42. C. Li, R.A. Newman, Q.P. Wu, S. Ke, W. Chen, T. Hutto, Z. Kan, M.D. Brannan, C. Charnsangavej, and S. Wallace Biodistribution of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor Cancer Chemother. Pharmacol. 46 2000 416 422
43. V. Omelyanenko, P. Kopeckova, C. Gentry, and J. Kopecek Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate J. Control. Release 53 1998 25 37 (Pubitemid 28218687)
44. P.S. Lai, P.J. Lou, C.L. Peng, C.L. Pai, W.N. Yen, M.Y. Huang, T.H. Young, and M.J. Shieh Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy J. Control. Release 122 2007 39 46
45. D. Belotti, M. Rieppi, M.I. Nicoletti, A.M. Casazza, T. Fojo, G. Taraboletti, and R. Giavazzi Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells Clin. Cancer Res. 2 1996 1725 1730 (Pubitemid 26356358)
46. D.I. Axel, W. Kunert, C. Goggelmann, M. Oberhoff, C. Herdeg, A. Kuttner, D.H. Wild, B.R. Brehm, R. Riessen, G. Koveker, and K.R. Karsch Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery Circulation 96 1997 636 645 (Pubitemid 27329445)
47. K. Miller, R. Erez, E. Segal, D. Shabat, and R. Satchi-Fainaro Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate Angew. Chem. Int. Ed. Engl. 48 2009 2949 2954
48. D. Landesman-Milo, M. Goldsmith, S. Leviatan Ben-Arye, B. Witenberg, E. Brown, S. Leibovitch, S. Azriel, S. Tabak, V. Morad, and D. Peer Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells Cancer Lett. 334 2013 221 227
49. S.M. Moghimi Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents Adv. Drug Deliv. Rev. 17 1995 103 115